<p>美國銀行證券分析師 Jason Zemansky 昨日維持了對 Travere Therapeutics 的買入評級，並設定了 50.00 美元的目標價。該公司的股票昨日收盤價為 44.10 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>根據 TipRanks，Zemansky 是一位五星級分析師，平均回報率為 19.9%，成功率為 56.33%。Zemansky 覆蓋醫療保健行業，專注於 Biogen、Insmed 和 Ligand Pharma 等股票。</p>
<p>目前，分析師對 Travere Therapeutics 的共識評級為強烈買入，平均目標價為 53.42 美元，代表 21.13% 的上漲空間。在 5 月 8 日發佈的一份報告中，H.C. Wainwright 也重申了該股票的買入評級，目標價為 57.00 美元。</p>

TVTX

<p>美國銀行證券分析師 Jason Zemansky 對 Travere Therapeutics (TVTX) 維持了買入評級，目標價為 50.00 美元。該股票收盤價為 44.10 美元。分析師共識為強烈買入，平均目標價為 53.42 美元，表明有 21.13% 的上漲空間。H.C. Wainwright 也重申了買入評級，目標價為 57.00 美元</p>

<p>Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $50.00. The company’s shares closed yesterday at $44.10.</p>
<div class="lb-trans"><p>美國銀行證券分析師 Jason Zemansky 昨日維持了對 Travere Therapeutics 的買入評級，並設定了 50.00 美元的目標價。該公司的股票昨日收盤價為 44.10 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>According to TipRanks, Zemansky is a 5-star analyst with an average return of 19.9% and a 56.33% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Biogen, Insmed, and Ligand Pharma.</p>
<div class="lb-trans"><p>根據 TipRanks，Zemansky 是一位五星級分析師，平均回報率為 19.9%，成功率為 56.33%。Zemansky 覆蓋醫療保健行業，專注於 Biogen、Insmed 和 Ligand Pharma 等股票。</p>
</div><p>Currently, the analyst consensus on Travere Therapeutics is a Strong Buy with an average price target of $53.42, representing a 21.13% upside. In a report released on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $57.00 price target.</p>
<div class="lb-trans"><p>目前，分析師對 Travere Therapeutics 的共識評級為強烈買入，平均目標價為 53.42 美元，代表 21.13% 的上漲空間。在 5 月 8 日發佈的一份報告中，H.C. Wainwright 也重申了該股票的買入評級，目標價為 57.00 美元。</p>
</div>

Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX)

Tip Ranks

Travere Therapeutics

美國銀行

Biogen

Insmed

Ligand制藥

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

美國銀行證券仍然維持對 Travere Therapeutics（TVTX）的買入評級